Bank of Montreal
KLRS

Bank of Montreal’s Kalaris Therapeutics KLRS Stock Holding History

Bank of Montreal’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-38
Closed -$21K – 5029
2021
Q1 		$21K Sell
38
-83
-69% -$69.8K ﹤0.01% 4046
2020
Q4 		$126K Buy
121
+85
+236% +$65.4K ﹤0.01% 3468
2020
Q3 		$25K Buy
+36
New +$24.6K ﹤0.01% 3744

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of Montreal's KLRS Position: Q2 2021 in Review

Bank of Montreal sold out of Kalaris Therapeutics (KLRS) in Q2 2021, closing a stake of 38 shares — an estimated $21K sold.

Bank of Montreal first reported a position in KLRS in Q3 2020 and held it in 3 quarters. The position peaked at $126K in Q4 2020. 84 funds tracked by Wall St. Rank hold KLRS as of Q2 2021.

  • Bank of Montreal reported no remaining Kalaris Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Bank of Montreal sold 38 Kalaris Therapeutics shares in Q2 2021, an estimated $21K.
  • Bank of Montreal first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 3 quarters.
  • Bank of Montreal's Kalaris Therapeutics position peaked at $126K in Q4 2020.
  • 84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2021.

Based on Bank of Montreal's 13F filing for Q2 2021, filed 12 Aug 2021.